# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add Bunker Ke	dress of Reporting vin D.	) Person <sup>*</sup>	2. Issuer Name and Ticker or Trading Symbol Zentalis Pharmaceuticals, Inc. [ZNTL]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify
	(First) LIS PHARMAC WAY SUITE 1	(Middle) CEUTICALS, INC. 1710	3. Date of Earliest Transaction (Month/Day/Year) 02/13/2023	X Once (give the Other (specify below) below) Chief Scientific Officer
(Street) NEW YORK (City)			4. If Amendment, Date of Original Filed (Month/Day/Year)	<ul> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) 2A. Deeme Execution if any (Month/Day		tion Date, Transaction		4. Securities Disposed O		ed (A) or tr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			
Common Stock	02/13/2023		<b>S</b> <sup>(1)</sup>		3,807	D	\$20.4244 <sup>(2)</sup>	871,657	D		
Common Stock	02/14/2023		<b>S</b> <sup>(3)</sup>		6,500	D	<b>\$</b> 19.9805 <sup>(4)</sup>	865,157	D		
Common Stock								350	I	As UTMA custodian for sons	
Common Stock								95,000	I	See Footnote <sup>(5)</sup>	

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v			Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$19.79 to \$20.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires July 31, 2023.

4. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$19.73 to \$20.29. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.

## **Remarks:**

By: /s/ Melissa B. Epperly,

Attorney-in-Fact for Kevin D. 02/14/2023

Bunker

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.